Results 111 to 120 of about 2,552 (169)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2004
Tiotropium bromide is a novel, inhaled, once-daily anticholinergic bronchodilator that has recently been approved in the United States for use in patients with COPD. Its unique feature is the persistence of bronchodilation for > 24 h due to prolonged M(3) muscarinic receptor blockade.
Cynthia Mundy, Peter Kirkpatrick
exaly +6 more sources
Tiotropium bromide is a novel, inhaled, once-daily anticholinergic bronchodilator that has recently been approved in the United States for use in patients with COPD. Its unique feature is the persistence of bronchodilation for > 24 h due to prolonged M(3) muscarinic receptor blockade.
Cynthia Mundy, Peter Kirkpatrick
exaly +6 more sources
Drugs, 2002
Tiotropium bromide is an anticholinergic bronchodilator that antagonises muscarinic M(1), M(2) and M(3) receptors. It dissociates more slowly from M(1) receptors and, importantly, from M(3) receptors (which are located in bronchial smooth muscle) than from M(2) receptors and subsequently has a long duration of action permitting once-daily ...
Karen M, Hvizdos, Karen L, Goa
+6 more sources
Tiotropium bromide is an anticholinergic bronchodilator that antagonises muscarinic M(1), M(2) and M(3) receptors. It dissociates more slowly from M(1) receptors and, importantly, from M(3) receptors (which are located in bronchial smooth muscle) than from M(2) receptors and subsequently has a long duration of action permitting once-daily ...
Karen M, Hvizdos, Karen L, Goa
+6 more sources
Expert Opinion on Investigational Drugs, 2001
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire +2 more sources
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire +2 more sources
Olodaterol + tiotropium bromide for the treatment of COPD
Expert Review of Respiratory Medicine, 2016Patients suffering from COPD not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Addition of a LABA to a LAMA induces a larger bronchodilation than that obtained with the LAMA as monotherapy and also improves many patient-reported outcomes.
Calzetta L. +3 more
openaire +5 more sources
Safety and pharmacological profile of tiotropium bromide
Expert Opinion on Drug Safety, 2009Chronic obstructive pulmonary disease (COPD) is associated with progressive airflow obstruction and is characterized by a high risk of morbidity and mortality. With early detection and treatment, the natural history of this disease may be improved. So far, bronchodilator therapy is the most important treatment for COPD.
P. Santus, F. Di Marco
openaire +2 more sources
Tiotropium Bromide in Children and Adolescents with Asthma
Pediatric Drugs, 2017Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA approved in children and adolescents. As the use of tiotropium becomes more common in clinical practice, it is necessary to review the existing data to identify patients who may benefit from
Hengameh H, Raissy, H William, Kelly
openaire +2 more sources